MXPA03005915A - Derivados de indol y su uso como ligandos receptores de 5-ht2b y 5-ht2c. - Google Patents

Derivados de indol y su uso como ligandos receptores de 5-ht2b y 5-ht2c.

Info

Publication number: MXPA03005915A
Authority: MX; Mexico
Prior art keywords: ht2b; receptor ligands; indole derivatives; ht2c receptor; ht2c
Prior art date: 2000-12-27

Application number

MXPA03005915A

Other languages

English (en)

Inventor

Hebeisen Paul

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-27

Filing date

2001-12-14

Publication date

2003-09-10

2000-12-27 Priority claimed from GB0031724A external-priority patent/GB0031724D0/en

2001-08-14 Priority claimed from GB0119820A external-priority patent/GB0119820D0/en

2001-12-14 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2003-09-10 Publication of MXPA03005915A publication Critical patent/MXPA03005915A/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Addiction (AREA)
Child & Adolescent Psychology (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Nutrition Science (AREA)
Emergency Medicine (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MXPA03005915A 2000-12-27 2001-12-14 Derivados de indol y su uso como ligandos receptores de 5-ht2b y 5-ht2c. MXPA03005915A (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0031724A GB0031724D0 (en)	2000-12-27	2000-12-27	Indole derivatives
GB0119820A GB0119820D0 (en)	2001-08-14	2001-08-14	Indole derivatives
PCT/EP2001/014781 WO2002051844A1 (en)	2000-12-27	2001-12-14	Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands

Publications (1)

Publication Number	Publication Date
MXPA03005915A true MXPA03005915A (es)	2003-09-10

Family

ID=26245498

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MXPA03005915A MXPA03005915A (es)	2000-12-27	2001-12-14	Derivados de indol y su uso como ligandos receptores de 5-ht2b y 5-ht2c.

Country Status (16)

Country	Link
US (1)	US6610685B2 (es)
EP (1)	EP1347979B1 (es)
JP (1)	JP4094950B2 (es)
KR (1)	KR100539143B1 (es)
CN (1)	CN1250549C (es)
AR (1)	AR035722A1 (es)
AT (1)	ATE369368T1 (es)
AU (1)	AU2002228007B2 (es)
BR (1)	BR0116605A (es)
CA (1)	CA2432085C (es)
DE (1)	DE60129841T2 (es)
ES (1)	ES2291374T3 (es)
MX (1)	MXPA03005915A (es)
PE (1)	PE20020911A1 (es)
UY (1)	UY27097A1 (es)
WO (1)	WO2002051844A1 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ536664A (en)	2002-06-19	2007-07-27	Biovitrum Ab	Piperazinylpyrazine derivative compounds, their use and preparation
US7105526B2 (en)	2002-06-28	2006-09-12	Banyu Pharmaceuticals Co., Ltd.	Benzimidazole derivatives
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
CL2004000826A1 (es)	2003-04-25	2005-03-04	Pfizer	Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
GB0314967D0 (en) *	2003-06-26	2003-07-30	Hoffmann La Roche	Piperazine derivatives
ATE547404T1 (de)	2003-09-22	2012-03-15	Msd Kk	Piperidinderivate
EP1734963A4 (en)	2004-04-02	2008-06-18	Merck & Co Inc	METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
JP5173190B2 (ja)	2004-08-25	2013-03-27	武田薬品工業株式会社	腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
EP2286837A3 (en)	2004-11-01	2013-09-04	Amylin Pharmaceuticals, LLC	Treatment of obesity and obesity related diseases
US7608626B2 (en)	2004-11-01	2009-10-27	Wyeth	Substituted indolizines and derivatives as CNS agents
US8394765B2 (en)	2004-11-01	2013-03-12	Amylin Pharmaceuticals Llc	Methods of treating obesity with two different anti-obesity agents
US7737155B2 (en)	2005-05-17	2010-06-15	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
NZ562766A (en)	2005-05-30	2011-03-31	Banyu Pharma Co Ltd	Piperidine derivatives as histamine-H3 receptor antagonists
US20100216758A1 (en)	2005-08-10	2010-08-26	Makoto Ando	Pyridone Compounds
AU2006279680B2 (en)	2005-08-11	2012-12-06	Amylin Pharmaceuticals, Llc	Hybrid polypeptides with selectable properties
EP2330125A3 (en)	2005-08-11	2012-12-12	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides with selectable properties
AU2006282260A1 (en)	2005-08-24	2007-03-01	Msd K.K.	Phenylpyridone derivative
EP1939194A4 (en)	2005-09-07	2010-12-08	Banyu Pharma Co Ltd	BICYCLIC AROMATIC SUBSTITUTED PYRIDONE DERIVATIVE
CN101277960A (zh)	2005-09-29	2008-10-01	默克公司	作为黑皮质素-4受体调节剂的酰化螺哌啶衍生物
WO2007048027A2 (en)	2005-10-21	2007-04-26	Novartis Ag	Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
CA2627139A1 (en)	2005-10-27	2007-05-03	Banyu Pharmaceutical Co., Ltd.	Novel benzoxathiin derivative
WO2007055418A1 (ja)	2005-11-10	2007-05-18	Banyu Pharmaceutical Co., Ltd.	アザ置換スピロ誘導体
AU2006324089A1 (en)	2005-12-09	2007-06-14	F. Hoffmann-La Roche Ag	Tricyclic amide derivatives useful for treating obesity
WO2007132841A1 (ja)	2006-05-16	2007-11-22	Takeda Pharmaceutical Company Limited	縮合複素環化合物およびその用途
EP2698157B1 (en)	2006-09-22	2015-05-20	Merck Sharp & Dohme Corp.	Method of treatment using fatty acid synthesis inhibitors
AU2007301126A1 (en)	2006-09-28	2008-04-03	Banyu Pharmaceutical Co., Ltd.	Diaryl ketimine derivative
TWI629058B (zh)	2007-01-16	2018-07-11	陳建宏	醫藥組成物及其用途
JP5319518B2 (ja)	2007-04-02	2013-10-16	Ｍｓｄ株式会社	インドールジオン誘導体
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en)	2007-06-04	2008-12-11	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009063992A1 (ja)	2007-11-15	2009-05-22	Takeda Pharmaceutical Company Limited	縮合ピリジン誘導体およびその用途
JPWO2009110510A1 (ja)	2008-03-06	2011-07-14	Ｍｓｄ株式会社	アルキルアミノピリジン誘導体
US20110015198A1 (en)	2008-03-28	2011-01-20	Banyu Pharmaceutical Co., Inc.	Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
CA2666036C (en)	2008-05-16	2017-09-12	Chien-Hung Chen	Novel compositions and methods for treating hyperproliferative diseases
WO2009149279A2 (en)	2008-06-04	2009-12-10	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2727914A1 (en)	2008-06-19	2009-12-23	Banyu Pharmaceutical Co., Ltd.	Spirodiamine-diaryl ketoxime derivative technical field
CA2730603C (en)	2008-07-16	2019-09-24	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2319841A1 (en)	2008-07-30	2011-05-11	Msd K.K.	(5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
CA2741125A1 (en)	2008-10-22	2010-04-29	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2009308980B2 (en)	2008-10-30	2013-02-28	Merck Sharp & Dohme Corp.	Isonicotinamide orexin receptor antagonists
WO2010051206A1 (en)	2008-10-31	2010-05-06	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US20110243940A1 (en)	2008-12-16	2011-10-06	Schering Corporation	Bicyclic pyranone derivatives and methods of use thereof
WO2010075068A1 (en)	2008-12-16	2010-07-01	Schering Corporation	Pyridopyrimidine derivatives and methods of use thereof
JPWO2011071136A1 (ja)	2009-12-11	2013-04-22	アステラス製薬株式会社	線維筋痛症治療剤
US8895596B2 (en)	2010-02-25	2014-11-25	Merck Sharp & Dohme Corp	Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
BR112013021236B1 (pt)	2011-02-25	2021-05-25	Merck Sharp & Dohme Corp	composto derivado de benzimidazol, e, composição
KR102034748B1 (ko)	2011-03-01	2019-10-21	시너지 파마슈티컬즈 인코포레이티드	구아닐레이트 사이클라제 c 작용제의 제조 방법
AR088352A1 (es)	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US9527875B2 (en)	2012-08-02	2016-12-27	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
US9650375B2 (en)	2013-03-14	2017-05-16	Merck Sharp & Dohme Corp.	Indole derivatives useful as anti-diabetic agents
EP2970384A1 (en)	2013-03-15	2016-01-20	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
WO2014151200A2 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
AU2014274812B2 (en)	2013-06-05	2018-09-27	Bausch Health Ireland Limited	Ultra-pure agonists of guanylate cyclase C, method of making and using same
DK3186242T3 (da)	2014-08-29	2021-12-20	Tes Pharma S R L	Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
AR109950A1 (es)	2016-10-14	2019-02-06	Tes Pharma S R L	INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
JPWO2019131902A1 (ja)	2017-12-27	2020-12-10	武田薬品工業株式会社	腹圧性尿失禁および便失禁の治療薬
BR112021009589A2 (pt)	2018-11-20	2021-08-17	Tes Pharma S.R.L.	inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
US11098029B2 (en)	2019-02-13	2021-08-24	Merck Sharp & Dohme Corp.	5-alkyl pyrrolidine orexin receptor agonists
US12331018B2 (en)	2019-02-13	2025-06-17	Merck Sharp & Dohme Llc	Pyrrolidine orexin receptor agonists
WO2021026047A1 (en)	2019-08-08	2021-02-11	Merck Sharp & Dohme Corp.	Heteroaryl pyrrolidine and piperidine orexin receptor agonists
MX2023001840A (es)	2020-08-18	2023-03-13	Merck Sharp & Dohme Llc	Agonistas de bicicloheptano pirrolidina de los receptores de orexina.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1247547A (en)	1983-06-22	1988-12-28	Paul Hadvary	Leucine derivatives
CA1328881C (en)	1984-12-21	1994-04-26	Pierre Barbier	Process for the manufacture of oxetanones
CA1270837A (en)	1984-12-21	1990-06-26	Hoffmann-La Roche Limited	Oxetanones
CA2035972C (en)	1990-02-23	2006-07-11	Martin Karpf	Process for the preparation of oxetanones
US5274143A (en)	1991-07-23	1993-12-28	Hoffmann-La Roche Inc.	Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
TW270114B (es)	1993-10-22	1996-02-11	Hoffmann La Roche
TW334423B (en) *	1993-10-22	1998-06-21	Hoffmann La Roche	Tricyclic 1-aminoethylpyrrole-derivatives
AU5343298A (en)	1997-01-13	1998-08-03	Yamanouchi Pharmaceutical Co., Ltd.	5-ht2c receptor agonists and aminoalkylindazole derivatives
US6004996A (en)	1997-02-05	1999-12-21	Hoffman-La Roche Inc.	Tetrahydrolipstatin containing compositions
US6267952B1 (en)	1998-01-09	2001-07-31	Geltex Pharmaceuticals, Inc.	Lipase inhibiting polymers
CN1170534C (zh)	1998-08-14	2004-10-13	霍夫曼-拉罗奇有限公司	含有脂酶抑制剂的药物组合物
JP3761783B2 (ja)	1998-08-14	2006-03-29	エフ．ホフマン−ラロシュアーゲー	リパーゼ阻害剤とキトサンを含む製薬学的組成物
GB9819035D0 (en) *	1998-09-01	1998-10-28	Cerebrus Res Ltd	Chemical compounds VII
CZ20012193A3 (cs) *	1998-12-17	2001-12-12	American Home Products Corporation	Deriváty 2,3,4,4a-tetrahydro-1H-pyrazino(1,2-a)chinoxalin-5(6H)onu, způsob jejich výroby a jejich pouľití
EP1132389A1 (en) *	2000-03-06	2001-09-12	Vernalis Research Limited	New aza-indolyl derivatives for the treatment of obesity

2001
- 2001-12-14 KR KR10-2003-7008679A patent/KR100539143B1/ko not_active Expired - Fee Related
- 2001-12-14 CA CA002432085A patent/CA2432085C/en not_active Expired - Fee Related
- 2001-12-14 AT AT01989597T patent/ATE369368T1/de not_active IP Right Cessation
- 2001-12-14 DE DE60129841T patent/DE60129841T2/de not_active Expired - Lifetime
- 2001-12-14 AU AU2002228007A patent/AU2002228007B2/en not_active Ceased
- 2001-12-14 CN CNB018213510A patent/CN1250549C/zh not_active Expired - Fee Related
- 2001-12-14 ES ES01989597T patent/ES2291374T3/es not_active Expired - Lifetime
- 2001-12-14 JP JP2002552939A patent/JP4094950B2/ja not_active Expired - Fee Related
- 2001-12-14 US US10/017,978 patent/US6610685B2/en not_active Expired - Fee Related
- 2001-12-14 MX MXPA03005915A patent/MXPA03005915A/es active IP Right Grant
- 2001-12-14 WO PCT/EP2001/014781 patent/WO2002051844A1/en not_active Ceased
- 2001-12-14 EP EP01989597A patent/EP1347979B1/en not_active Expired - Lifetime
- 2001-12-14 BR BR0116605-0A patent/BR0116605A/pt not_active IP Right Cessation
- 2001-12-21 PE PE2001001298A patent/PE20020911A1/es not_active Application Discontinuation
- 2001-12-21 AR ARP010106000A patent/AR035722A1/es not_active Application Discontinuation
- 2001-12-26 UY UY27097A patent/UY27097A1/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
PE20020911A1 (es)	2002-10-22
DE60129841D1 (de)	2007-09-20
WO2002051844A1 (en)	2002-07-04
KR100539143B1 (ko)	2005-12-26
ES2291374T3 (es)	2008-03-01
UY27097A1 (es)	2002-07-31
ATE369368T1 (de)	2007-08-15
CA2432085A1 (en)	2002-07-04
AU2002228007B8 (en)	2002-07-08
BR0116605A (pt)	2003-09-30
JP2004517852A (ja)	2004-06-17
AU2002228007B2 (en)	2007-06-21
US20020160997A1 (en)	2002-10-31
KR20030063476A (ko)	2003-07-28
CA2432085C (en)	2009-02-24
EP1347979A1 (en)	2003-10-01
AR035722A1 (es)	2004-07-07
JP4094950B2 (ja)	2008-06-04
DE60129841T2 (de)	2008-04-17
CN1483034A (zh)	2004-03-17
US6610685B2 (en)	2003-08-26
CN1250549C (zh)	2006-04-12
EP1347979B1 (en)	2007-08-08

Publication	Publication Date	Title
MXPA03005915A (es)	2003-09-10	Derivados de indol y su uso como ligandos receptores de 5-ht2b y 5-ht2c.
MXPA03003246A (es)	2003-06-06	Derivados de indolina y su uso como ligandos del receptor 5-ht2.
MXPA03005648A (es)	2003-10-06	Derivados de carbazol y su uso, como ligandos de receptor del neuropeptido y5.
IL152085A0 (en)	2003-05-29	Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
AU5637199A (en)	2000-03-21	Indoline derivatives as 5-ht2b and/or 5-ht2c receptor ligands
PL353969A1 (en)	2003-12-15	Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof as adenosine receptor ligands
ZA200203316B (en)	2004-02-25	New use and novel n-azabicyclo-amide derivatives.
HUP0400249A3 (en)	2009-01-28	Pyridine derivatives as 5-ht receptor ligands and uses thereof
IL155634A0 (en)	2003-11-23	3-arylindole derivatives and their use as cb2 receptor agonists
GB2384776B (en)	2004-03-03	Phthalazinone derivatives
MXPA02008801A (es)	2003-07-07	Derivados de indol, proceso para la preparacion de los mismos y su uso.
MXPA02001508A (es)	2003-07-21	Derivados de arilmetil-carbonilamino-tiazol y sus usos como agentes antitumorales.
AU2001246671A1 (en)	2002-01-03	Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
MXPA03003039A (es)	2003-10-15	Derivados de indola y bencimidazola como moduladores del receptor crf.
AU2002217287A1 (en)	2002-07-01	Benzo(f) isoindol derivatives and their use as ep4 receptor ligands
MXPA03004644A (es)	2003-09-05	Derivados de fenilacetamdia-pirazol y su uso como agentes antitumorales.
GB0012934D0 (en)	2000-07-19	Thermal tracer
IL151154A0 (en)	2003-04-10	Indol-3-yl derivatives
ZA200207489B (en)	2003-12-18	Apomorphine derivatives and methods for their use.
HUP0203961A3 (en)	2003-05-28	3-phenoxy-1-phenyl acetylene derivatives and their use as herbicedes
AU8664701A (en)	2002-03-22	Oxindole derivatives
MXPA03004136A (es)	2003-08-19	Derivados de pirimidina y su uso como ligandos del receptor de neuropeptido y (npy).
MXPA03000644A (es)	2003-06-06	Nuevos derivados de indol y uso como medicamentos.
MXPA01012041A (es)	2003-09-04	Derivados de indol.
AU2001259051A1 (en)	2001-11-26	Piperidyindoles as serotonin receptor ligands

Legal Events

Date	Code	Title	Description
2006-04-28	FG	Grant or registration